Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594797 | 0.86 | ALDH1A1 (0.72) | MAPTKDM4EALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL9650155 | 0.85 | CHEK1 (0.50) | MAPTKDM4EALDH1A1HDAC1TSHR | |
| SCHEMBL14933944 | 0.85 | ALDH1A1 (0.53) | MAPTKDM4EALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL1595017 | 0.85 | MAPT (0.48) | MAPTKDM4EALDH1A1NPSR1LMNA | |
| SCHEMBL3858593 | 0.85 | MEN1 (0.52) | MAPTALDH1A1NPSR1SMN1; SMN2LMNA | |
| SCHEMBL11316660 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1NPSR1SMN1; SMN2LMNA | |
| SCHEMBL14063303 | 0.84 | HCAR3 (0.65) | MAPTKDM4EALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL8107611 | 0.83 | MAPT (0.60) | MAPTKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9760920 | 0.83 | LMNA (0.55) | MAPTALDH1A1NPSR1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL9652307 | 0.83 | CHEK1 (0.48) | MAPTKDM4EALDH1A1HDAC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919510-B2 | treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain; selectively inhibits neuronal nitric oxide synthase (nNOS) over endothelial nitric oxide synthase (eNOS) and/or inducible nitric oxide synthase (iNOS) | NEURAXON, INC (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-1888568-A4 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON INC (CA) | 2009-08-12 | — | — | EP | disclosed |
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | NEURAXON, INC (CA) | 2008-09-04 | — | — | US | disclosed |
| EP-1888568-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | Neuraxon Inc. (CA) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214613-A1 | Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity | OPRM1, NOS1, OPRK1 | MAPT 2356/4885KDM4E 1942/4885ALDH1A1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.